ATEC

AI Memo

Alphatec

As of 2026-09-28/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Next results test surgeon adoption and case economics • 2026-11-05

Base target: $10 / p=45% prob

Biggest risk

Q2 GAAP net loss was $26 million despite $36 million of adjusted EBITDA [#SEC-8K-2026-08-04]. Revenue-per-case pressure and dependence on continued adoption leave execution risk [#PR-EARNINGS-2026-08-12]. The deterministic score's negative directional prior argues against upgrading the thesis on the strength of one quarter.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

Q2 growth in cases and surgeon users, positive free cash flow, and higher adjusted EBITDA guidance show improving scale economics [#SEC-8K-2026-08-04]. CEO Patrick Miles's September open-market purchase is an alignment signal, not proof of future results [#SEC-FORM4-2026-09-10].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-28

Base target

$10

p=45%

Bull target

$14

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

EOS Insight procedural pull-through
Q2 growth in cases and surgeon users, positive free cash flow, and higher adjusted EBITDA guidance show improving scale economics [#SEC-8K-2026-08-04].
CEO Patrick Miles's September open-market purchase is an alignment signal, not proof of future results [#SEC-FORM4-2026-09-10].

BearKey bullets

ATEC reported a $26 million GAAP net loss; adjusted EBITDA excludes items and should not be treated as GAAP profitability [#SEC-8K-2026-08-04].
EOS Insight pull-through lacks a quantified, independently confirmed forward adoption timetable in the supplied evidence.
Failure to deliver approximately $882 million of 2026 revenue, $140 million of adjusted EBITDA, or at least $20 million of free cash flow could pressure the shares [#SEC-8K-2026-08-04].

WatchKey bullets

Next results test surgeon adoption and case economics

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $10 (p=45%)

Target spread vs base: +42% / -32%

Scenario probabilities

Bull Target: $14 (p=25%)Base Target: $10 (p=45%)Bear Target: $7 (p=30%)

Commentary

Primary-source Q2 operating evidence is constructive, but it predates the September 25 price anchor. The CEO purchase offers only an alignment signal. Verified post-print analyst revisions, attributable earnings-day price reaction, options skew, short interest, employee sentiment, and sufficient social coverage are unavailable; zero-valued sentiment fields mean unavailable, not neutral. The negative deterministic directional prior and untested full-year execution support cautious monitoring.

As of 2026-09-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

EOS Insight procedural pull-through

Scenarios

Bull Target (Scenario probability)

$14 / p=25% prob

Base Target (Scenario probability)

$10 / p=45% prob

Bear Target (Scenario probability)

$7 / p=30% prob

Analysis 2026-09-28 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Next results test surgeon adoption and case economics
Q2 surgical revenue grew 17%, case volume grew 20%, and net new surgeon users increased 24%. The next report will test whether that growth persists and converts into revenue per case; management said Q2 revenue per case declined approximately 2.7% year over year. The reporting date is an estimate, not a company announcement [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-12].
Prob 55.00% • Move -8.00% • Priced-in 45.00%
EVENT2027-02-28
Full-year profitability and cash-flow delivery
ATEC reaffirmed approximately $882 million of 2026 revenue, raised adjusted EBITDA guidance from approximately $134 million to $140 million, and retained guidance for at least $20 million of free cash flow. Delivery would support the operating-leverage case; a shortfall would challenge it [#SEC-8K-2026-08-04].
Prob 60.00% • Move 12.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

EOS Insight procedural pull-through
2027-09-30
Management described EOS Insight as a potential driver of subsequent surgical hardware usage. Sustained, disclosed evidence of that pull-through could strengthen the growth case, but the supplied transcript excerpt does not establish its scale or timing [#PR-EARNINGS-2026-08-12].
Prob 45% • Move 15% • Priced-in 30%

Risks

ATEC reported a $26 million GAAP net loss; adjusted EBITDA excludes items and should not be treated as GAAP profitability [#SEC-8K-2026-08-04].
EOS Insight pull-through lacks a quantified, independently confirmed forward adoption timetable in the supplied evidence.
Failure to deliver approximately $882 million of 2026 revenue, $140 million of adjusted EBITDA, or at least $20 million of free cash flow could pressure the shares [#SEC-8K-2026-08-04].
Q2 revenue per case declined approximately 2.7% year over year, reflecting case mix, international growth, and weaker biologics attachment [#PR-EARNINGS-2026-08-12].

Peers

Symbol	Summary
GMED	Globus Medical is a direct spine-device comparator, although its broader musculoskeletal portfolio and greater scale limit valuation comparability. Its filing identifies Alphatec among competitors. Globus 2025 Form 10-K
MDT	Medtronic provides a spine-technology competitive benchmark, but its diversified businesses and much greater scale make company-wide multiples a weak direct comparison. Medtronic spinal-technology business

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-28

Loading AI feed…

Symbol

Summary

GMED

Globus Medical is a direct spine-device comparator, although its broader musculoskeletal portfolio and greater scale limit valuation comparability. Its filing identifies Alphatec among competitors. Globus 2025 Form 10-K

MDT

Medtronic provides a spine-technology competitive benchmark, but its diversified businesses and much greater scale make company-wide multiples a weak direct comparison. Medtronic spinal-technology business